Traders should monitor for future disclosures that may reveal the size of the stake and conversion terms, especially as KLRA approaches a potential IPO. The lack of disclosed quantities limits immediate trading implications, but the filing confirms ongoing involvement by a major pharmaceutical parent.
Price Chart
Executive Summary
Jiangsu Hengrui Pharmaceuticals Co., Ltd. filed a Form 3 disclosing beneficial ownership of Kailera Therapeutics, Inc. (KLRA) through its wholly-owned subsidiary Hengrui (USA) Ltd. The filing reports holdings of Series A-2 convertible preferred stock, which will automatically convert into common stock upon KLRA's IPO. No specific financial figures such as total shares or conversion ratios are disclosed in the filing.
Key Facts
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. is the reporting entity, filing on behalf of its wholly-owned subsidiary Hengrui (USA) Ltd.
- Hengrui (USA) Ltd. holds Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock in Kailera Therapeutics, Inc. (KLRA).
- The preferred shares are convertible at the holder's election and will automatically convert into common stock immediately prior to KLRA's IPO.
- The filing does not disclose the number of shares held, dollar value, or percentage ownership.
- This is an initial ownership filing (Form 3), indicating new reporting of beneficial ownership.
Financial Impact
undisclosed amount
Risk Factors
- Potential future dilution upon conversion of preferred shares if KLRA proceeds with an IPO
- Lack of transparency around stake size and conversion ratio limits assessment of economic impact
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001104659-26-044508 |
| Document: 0001104659-26-044508-index.html | 0001104659-26-044508 |
| Document: 0001104659-26-044508.txt | 0001104659-26-044508 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access